157 related articles for article (PubMed ID: 23616333)
21. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
Fust K; Li X; Maschio M; Barron R; Weinstein MC; Parthan A; Walli-Attaei M; Chandler DB; Lyman GH
Gynecol Oncol; 2014 Jun; 133(3):446-53. PubMed ID: 24657302
[TBL] [Abstract][Full Text] [Related]
23. Tumor lysis syndrome in extensive-stage small-cell lung cancer.
Beriwal S; Singh S; Garcia-Young JA
Am J Clin Oncol; 2002 Oct; 25(5):474-5. PubMed ID: 12393987
[TBL] [Abstract][Full Text] [Related]
24. Advanced epithelial ovarian cancer: from standard chemotherapy to promising molecular pathway targets--where are we now?
Syrios J; Banerjee S; Kaye SB
Anticancer Res; 2014 May; 34(5):2069-77. PubMed ID: 24778008
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies.
Pei Y; Li Y; Liang Y; Xu L; Huang X; Li Y; Tang W; Jiang X
Int J Clin Pharm; 2020 Dec; 42(6):1440-1446. PubMed ID: 32974856
[TBL] [Abstract][Full Text] [Related]
26. Tumor lysis syndrome associated with weekly paclitaxel treatment in a case with ovarian cancer.
Yahata T; Nishikawa N; Aoki Y; Tanaka K
Gynecol Oncol; 2006 Nov; 103(2):752-4. PubMed ID: 16857250
[TBL] [Abstract][Full Text] [Related]
27. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.
Deng J; Wang L; Chen H; Li L; Ma Y; Ni J; Li Y
Cancer Metastasis Rev; 2013 Dec; 32(3-4):535-51. PubMed ID: 23609751
[TBL] [Abstract][Full Text] [Related]
28. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.
Jaskiewicz AD; Herrington JD; Wong L
Pharmacotherapy; 2005 Dec; 25(12):1820-5. PubMed ID: 16305302
[TBL] [Abstract][Full Text] [Related]
29. Tumour lysis syndrome as a rare complication of chemotherapy in paediatric Wilms' Tumour: a case report.
Qamar S; Sindhu II; Shaheen N
J Pak Med Assoc; 2023 Mar; 73(3):700-704. PubMed ID: 36932788
[TBL] [Abstract][Full Text] [Related]
30. A case of occult bowel perforation after a cycle of chemotherapy for advanced epithelial ovarian carcinoma.
Zhou X; Hu P; Yue Y; Duan Z
Eur J Gynaecol Oncol; 2012; 33(5):540-2. PubMed ID: 23185808
[TBL] [Abstract][Full Text] [Related]
31. [Tumor lysis syndrome].
Downey AI; Cortés Guerreri V; Freue RD; Ludueña AV
Medicina (B Aires); 2019; 79(6):516-519. PubMed ID: 31829957
[TBL] [Abstract][Full Text] [Related]
32. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.
Hou MM; Wang Z; Janku F; Piha-Paul S; Naing A; Hong D; Westin S; Coleman RL; Sood AK; Tsimberidou AM; Subbiah V; Wheler J; Zinner R; Lu K; Meric-Bernstam F; Fu S
Oncotarget; 2016 Jun; 7(23):35132-43. PubMed ID: 27147567
[TBL] [Abstract][Full Text] [Related]
33. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.
Garcia AA; Sill MW; Lankes HA; Godwin AK; Mannel RS; Armstrong DK; Carolla RL; Liepman MK; Spirtos NM; Fischer EG; Leslie KK
Gynecol Oncol; 2012 Mar; 124(3):569-74. PubMed ID: 22037316
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
[TBL] [Abstract][Full Text] [Related]
35. Tumour lysis syndrome after treatment of chronic lymphocytic leukaemia with fludarabine.
Montalban C; Liaño F; Aguilera A
Postgrad Med J; 1994 Sep; 70(827):651-2. PubMed ID: 7971632
[TBL] [Abstract][Full Text] [Related]
36. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.
Taylor SE; Beck TL; Krivak TC; Zorn KK; Kelley JL; Edwards RP
Gynecol Oncol; 2014 Jul; 134(1):68-72. PubMed ID: 24769036
[TBL] [Abstract][Full Text] [Related]
37. Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients.
Wilbaux M; Hénin E; Oza A; Colomban O; Pujade-Lauraine E; Freyer G; Tod M; You B
Br J Cancer; 2014 Mar; 110(6):1517-24. PubMed ID: 24556626
[TBL] [Abstract][Full Text] [Related]
38. Tumor lysis syndrome in a nonsmall cell lung cancer.
Noyes AM; Lonial K; Siegel RD
Conn Med; 2014 Aug; 78(7):421-3. PubMed ID: 25195308
[TBL] [Abstract][Full Text] [Related]
39. Tumour lysis in newborn: spontaneous or secondary to antenatal steroids?
Ponmudi NJ; Beryl S; Santhanam S; Beck M
BMJ Case Rep; 2018 Apr; 2018():. PubMed ID: 29618468
[TBL] [Abstract][Full Text] [Related]
40. Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.
Oliva P; Decio A; Castiglioni V; Bassi A; Pesenti E; Cesca M; Scanziani E; Belotti D; Giavazzi R
Br J Cancer; 2012 Jul; 107(2):360-9. PubMed ID: 22713663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
